"This will evolve pretty rapidly," said the company's CEO, who has ties to UC Berkeley.
Halper Sadeh LLC, an investor rights law firm, is investigating the sale of Soleno Therapeutics, Inc. (NASDAQ: SLNO) to Neurocrine Biosciences for $53.00 per share in cash.
一些您可能无法访问的结果已被隐去。
显示无法访问的结果